key: cord-0764771-85al3u12 authors: Oronsky, Bryan; Gruber, Harry E; Reiners, Wendy; Reid, Tony R title: A Short Discussion About The SARS-CoV-2 mRNA-1273 Vaccine date: 2021-01-23 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.01.048 sha: 82efac25358f5ff1f91e34a492e9e80c5f71c2d6 doc_id: 764771 cord_uid: 85al3u12 The COVID-19 global pandemic has prompted accelerated vaccine development efforts. This perspective discusses the importance of SARS-CoV-2 vaccine candidates’ recruitment of cellular T-cell immunity and encourages industry to increasingly investigate and publish parameters related to cellular immunity in their research reports. Vaccine SARS-CoV-2 has caused an international health crisis that is only second in severity to the 1918 influenza pandemic (Taubenberger et al. 2006 ) and for which current development efforts to contain its wildfire-like spread with a safe and effective vaccine constitute a dire necessity and an immediate call to action; while success with one or more of the vaccine candidates is assumed and anxiously anticipated, it is not guaranteed due to compressed development timelines, the likely lack of results from long term testing, the inchoateness of knowledge regarding betacoronavirus immunology and the correctness of current vaccine strategies, most of which are based on presentation of the mutation-prone Spike protein with the reported potential to lead to exacerbation of disease through antibody dependent enhancement (ADE). Moreover, all vaccine candidates against Middle East respiratory syndrome coronavirus (MERS-CoV) have to date been unsuccessful despite considerable expenditure of effort and money, especially in Saudi Arabia for the protection of commercially valuable camels and horses. (Moore et al. 2020 ) So much depends on the rapid availability of a SARS-CoV-2 vaccine from a public health perspective that the slow and steady pace of conventional vaccine trials has been accelerated at "Warp Speed" (Funk et al. 2020) Here are a few caveats and interpretive qualifications of the above paragraph: concentrations of Spike peptide, thereby bypassing the normal antigen processing and presentation pathways that naturally operate in vivo. Hence, it is J o u r n a l P r e -p r o o f unknown whether or even if these Th1-like cells are predictive of vaccine-induced protection 2. the question of whether CD4+ activation leads to a post-vaccination increase of CD4 + memory T cells is not addressed, despite its potential importance, since the goal of this (or any) vaccine is the induction and maintenance of long-lived protective immunity. A study featuring non-human primates did evaluate the presence of memory T cells (Corbett et al. 2020) , however similar data from human participants would still be of interest to the public. The identification of cell surface markers, such as CD45RO and CD45RA, may permit a more detailed analysis of the memory and secondary effector potential of these CD4+ cells 3. also not addressed was the reported potential for Spike protein antibodies to induce antibody dependent enhancement (ADE) in which IgG Fc domains of infection bind to Fc receptors (FcRs) on monocytic phagocytes to facilitate viral entry and replication 4. the effect of the vaccine on anergic or exhausted T-cells was not evaluated, which is relevant for most at-risk elderly and immunocompromised patients, where lymphopenia and anergized T cells have been described as markers of COVID-19 severity (Huang et al. 2020) 5. given the ineffective endosome-to-cytosol translocation (Pardi et al. 2018 ), which has been described with mRNA vaccines, it is possible that the reduced CD8+ Tcell responses described in the manuscript are due to low MHC class I peptide It is impossible to understate the economic and societal importance of a safe, effective SARS-CoV-2 vaccine and, accordingly, the rapid roll-out of mRNA-1273 (and other advanced stage vaccine candidates) has been met with cautious optimism. Ultimately, however, only the results of large-scale Phase 3 trials, will determine whether, in fact, this optimism is justified. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic Prognostic Value of Leukocytosis and Lymphopenia for Coronavirus Disease Severity An mRNA Vaccine against SARS-CoV-2 -Preliminary Report Warp Speed" Needs Mind Melds, Not Warped Minds mRNA vaccines -a new era in vaccinology COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses Influenza: the mother of all pandemics The authors have no conflicts to disclose. Ethical Approval: Not applicable.